To evaluate the efficacy and safety of chemoradiation therapy with docetaxel, fluorouracil, and nedaplatin for the patients with esophageal cancer and simultaneous double primary malignancy. Three patients with inoperable disease were enrolled to receive the combination of docetaxel 40mg/m2 (on days 1 and 21), nedaplatin 10mg/body (on days 1∼5 and 21∼25), and fluorouracil 350mg/m2 (on days 1∼5 and 21∼25) with radiation (60Gy in 2-Gy fractions over 6 weeks). Evaluated responses were a complete response in 1 patient and partial responses in 2 pateints. The overall response rate was 100%. Myelosuppressions with grade 2 leukopenia occurred in 2 patients (66%). This chemoradiation therapy is effective for and well-tolerable by patients with esophageal cancer and simultaneous double primary malignancy.
